Immunic (IMUX)

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and Phase 2 clinical development for patients with relapsing and progressive multiple sclerosis, as well as moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Additionally, Immunic is working on IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.